NCT06408246

Stanford and University of Illinois Chicago ACE-D Study

Name: Clinical Trial NCT06408246
Creator: Stanford University
Keywords: Depression, Guanfacine, Phase 2, drug, clinical trial, United States of America

ACE-D: Accelerating Cognition-guided Signatures to Enhance Translation in Depression: Clinical Trial

Stanford University·Phase 2·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Depression
Drug/Device/Intervention: Guanfacine
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Stanford University
Location: Palo Alto,Chicago, United States of America

Timeline & enrollment

Phase: Phase 2
Start date: Feb 01, 2026
End date: Feb 01, 2029
Enrollment: 160 participants

Primary outcome

Remission of depressive symptoms

Summary

The purpose of this study is to understand how a psychotropic medication called guanfacine affects brain network functioning in humans, and how this function interacts with cognitive impairments in people experiencing depressive symptoms.

ICD-10 classifications

Depressive episodeOther depressive episodesRecurrent depressive disorderRecurrent depressive disorder, unspecifiedPost-schizophrenic depression

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06408246
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06408246 through Pure Global AI's free database. This Phase 2 trial is sponsored by Stanford University and is currently Not yet recruiting. The study focuses on Depression. Target enrollment is 160 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.